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Abstract: Cutaneous lupus erythematosus (CLE) encompasses a variety of lesions that may 
be refractory to systemic or topical agents. Discoid lupus erythematosus (DLE) and subacute 
cutaneous lupus erythematosus (SCLE) are the most common lesions in clinical practice. The 
topical calcineurin inhibitors, tacrolimus and pimecrolimus, have been used to treat resistant 
cutaneous lupus since 2002 and inhibit the proliferation and activation of T-cells and suppress 
immune-mediated cutaneous inflammation. This article reviews the mechanism of action, effi-
cacy, adverse effects, and the recent concern about their possible carcinogenic effect. Although 
the total number of patients is small and there is only one relevant randomized controlled study, 
the data are encouraging. Many patients, previously resistant to systemic agents or topical 
steroids, improved after four weeks of treatment. DLE and SCLE lesions were less responsive, 
reflecting the chronicity of the lesions, although more than 50% of patients still showed improve-
ment. Topical calcineurin inhibitors may be a safe and effective alternative to topical steroids 
for CLE although the only approved indication is for atopic dermatitis.
Keywords: tacrolimus, pimecrolimus, cutaneous lupus erythematosus, topical calcineurin 
inhibitors
Introduction
Cutaneous lesions are a common and often disfiguring manifestation of autoimmune 
connective tissue diseases. Cutaneous lupus erythematosus (CLE) is a broad term which 
includes a variety of lesions which may appear without the systemic manifestations 
of systemic lupus erythematosus (SLE). Pure CLE is usually not life-threatening, but 
frequently contributes to significant clinical and psychological morbidity, especially 
when lesions develop on the face. By contrast, cutaneous lesions commonly develop 
in patients with SLE.
The most widely used classifications of CLE are those of Gillian1 and Kuhn.2 The 
clinical manifestations of CLE are divided into acute (ACLE), subacute (SCLE), 
chronic (CCLE) and intermittent (ICLE) forms. ACLE typically presents in the con-
text of the systemic disease as a photosensitive, maculopapular rash over sun-exposed 
areas or as a localized malar rash. SCLE appears as annular polycyclic or psoriasiform 
lesions in sun-exposed areas without scarring. CCLE is further divided into discoid 
lupus erythematosus (DLE, scarring erythematosus macules or plaques with pigment 
changes localized to the upper part of the body, arms and face), lupus profundus (LEP, 
panniculitis) and chilblain lupus (CHLE, pernio-like skin lesions). ICLE presents as 
lupus tumidus (urticarial lesions in sun-exposed areas).Therapeutics and Clinical Risk Management 2010:6 96
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Administration of systemic agents such as corticosteroids, 
hydroxychloroquine, mepacrine, methotrexate, mycopheno-
late mofetil, cyclophosphamide and/or azathioprine for the 
underlying systemic disease leads in many cases to remission 
of the cutaneous lesions. The use of topical treatments such 
as steroids, and barrier sun protection in conjunction with 
systemic treatment usually provides additional benefit. 
Nevertheless, many patients suffer from resistant cutaneous 
lesions despite therapy. On the other hand, cutaneous lesions 
may be the only manifestation of disease such as SCLE and 
DLE, making it difficult to justify systemic agents, because 
of their side effects. A variety of systemic (dapsone, tha-
lidomide, retinoids, IV immunoglobulins) and topical agents 
(intralesional steroids, retinoids) as well as laser therapy, 
phototherapy, photopheresis, and cryotherapy have been used 
for resistant cutaneous lesions.3 There is a need therefore for 
alternative therapies.
The literature was systematically reviewed for all the 
articles involving topical calcineurin inhibitors by using the 
Medline search database. Search terms included tacrolimus, 
pimecrolimus, cutaneous lupus erythematosus and topical 
calcineurin inhibitors. All the publications involving clinical 
trials (prospective, retrospective, or case-controlled studies) 
in lupus patients were included in this review as well as many 
publications relevant to the pathophysiology of pimecrolimus 
and tacrolimus and experience in other diseases.
Topical calcineurin inhibitors
Tacrolimus (FK506) is a macrolide immunomodulator 
which was isolated in 1984 from the fungus Streptomyces 
Tsukubaensis, which was found near Tsukuba mountain in 
Ibraki, Japan. The word tacrolimus is derived from Tsukuba, 
macrolide and immunosuppression. Pimecrolimus (SDZ 
ASM 981) is a synthetic product of ascomycin which is a 
product of Streptomyces hygroscopicus.
These agents bind to the cytoplasmic protein macrophilin-
12, forming a complex that blocks the serine-threonine phos-
phatase calcineurin.4 Calcineurin is a protein that activates, by 
dephosphorylation, the cytoplasmic subunit of nuclear factor of 
activated T-cells (NF-AT), which enters the nucleus and forms a 
complex with the nuclear subunit promoting the production of 
many cytokines such as interleukin-2 (IL-2), IL-3, IL-4, IL-5, 
interferon-γ, and tumor necrosis factor-α (TNF-α).5–7
Calcineurin inhibitors inhibit T-cell activation. They also 
inhibit mast cell degranulation and release of inflamma-
tory mediators such as histamine, tryptase, and cytokines.8 
Pimecrolimus, but not tacrolimus, has no effects on dendritic 
cells and does not affect maturation of Langerhans cells in 
infants.9 Neither agent affects endothelial cells or fibroblasts, 
so do not cause skin atrophy or telangiectasis. Their propensity 
to pass through the skin is lower than that of steroids, avoiding 
any systemic side effects from their absorption.10 Pimecro-
limus is 20 times more lipophilic than tacrolimus, with a 
higher affinity for skin and lower permeation even in severely 
inflamed skin.11 On the other hand, tacrolimus has a stronger 
immunosuppressant capacity than pimecrolimus.12
Treatment indications
In 1989, oral tacrolimus was first used in preventing graft 
rejection after solid organ transplantation (liver, kidneys, 
lungs).13 In November 2000, tacrolimus ointment was 
approved by the US FDA Dermatologic Committee for the 
treatment of atopic dermatitis in children and adults and this 
remains the only approved indication.14,15
Since then, topical calcineurin inhibitors have been used 
off-label in many resistant cutaneous lesions in other dis-
eases such as psoriasis,16 localized scleroderma,17 chronic 
actinic dermatitis,18 pyoderma gangrenosum,19 Behçet’s dis-
ease,20 lichen planus,21 rheumatoid ulcers,22 steroid-induced 
rosacea,23 vitiligo,24 dermatomyositis,25 hand eczema,26 
asteatotic eczema,27 autoimmune bullous dermatosis,28 
seborrheic dermatitis,29 allergic contact dermatitis,30 and 
graft-versus-host disease.31 The commercially available 
forms are Protopic® or Prograf® 0.03% and 0.1% ointment 
(tacrolimus) and Elidel® 1% cream (pimecrolimus).
Safety
The topical calcineurin inhibitors appear to be safe for use in 
chronic inflammatory skin diseases.32 Side effects are usu-
ally mild, and include irritation, pruritus, burning sensation, 
or increased erythema. These adverse reactions are usually 
transient and subside with continuation oftreatment. Low 
penetration of the inflamed skin reduces the risks of any 
systemic side effects.
These agents seem to be a safer alternative to potent topi-
cal steroids, which usually are effective, cheap and fast-acting 
but their chronic use results in skin atrophy, teleangiectasiae, 
dermatitis, and pustules. Calcineurin inhibitors can be used 
safely over sensitive areas like the face, mucous membranes, 
and genitalia33 where the skin is thin, or during infancy 
and early childhood. They are not systemically absorbed 
even when large areas of skin are affected. They are highly 
effective even as monotherapy and they result in rapid and 
sustained improvement. There have been no reports of any 
statistically significant incidence of local infections (bacte-
rial, viral, or fungal) during their use,34 although there may 
be a slightly increased risk for local Varicella zoster virus, 
Herpes simplex virus, eczema herpeticum, impetigo, and Therapeutics and Clinical Risk Management 2010:6 97
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molluscum contagiosum.35 Clearly however, they should not 
be used in obviously infected skin lesions.
Although generally safe, in March 2005 the Food and 
Drug Administration (FDA) informed health care profes-
sionals and patients about a potential risk of cancer from 
the use of tacrolimus which was based on animal studies 
and case reports.36 The first report was that of a squamous 
cell cancer of the penis after use of tacrolimus.37 Since then, 
more than 19 cases of cancer were reported in association 
with tacrolimus use. Half of them involved lymphomas and 
the rest were skin tumors at the site of application (squamous 
cell carcinoma, sarcoma, melanoma).38,39 In animal models 
it was found that tacrolimus reduces the CD4/CD8 ratio in 
lymph nodes and that its concentration in the draining lymph 
nodes was as high as after oral use.40 Tacrolimus was also 
found to inhibit apoptosis in nonlymphoid cells and to affect 
proteins that participate in the cancer signaling pathways (Erk 
activation resulting in cell proliferation and p53 inhibition 
resulting in reduced apoptosis).41
On the other hand, many reviews and publications failed 
to connect topical calcineurin inhibitors with an increased 
risk of cancer42 in adults and children.43,44 There was no evi-
dence of systemic immunosuppression among infants treated 
intermittently with 1% pimecrolimus for up to two years, and 
all demonstrated a normal immune response to vaccinations 
without increased systemic or skin infections.45,46 The analy-
sis of data from clinical studies with more than five million 
patients treated with pimecrolimus cream since December 
2001 failed to show any increased risk of cancer.47
A recent study showed that topical calcineurin inhibitors 
were associated with a slightly increased risk of lymphoma 
compared with the general population, but the same risk was 
also noticed in users of topical steroids, suggesting that all 
topical treatments may increase lymphoma risk.48 Another 
study found an association between lymphoma (especially of 
the skin) and use of topical steroids but not with calcineurin 
inhibitors and that the risk depended on steroid potency and 
duration of exposure.49
Topical calcineurin inhibitors  
and cutaneous lupus erythematosus
Many case reports and a few prospective trials have been 
published since 2002 when lupus skin lesions were first 
treated with topical calcineurin inhibitors (see Table 1). The 
first report was by Yoshimasu et al50 who used tacrolimus 
ointment 0.1% once a day for four weeks in three SLE and 
Table 1 Topical calcineurin inhibitors in cutaneous lupus erythematosus
References Patients Treatment Successful treatment
48 3 SLE, 4 DLE tacrolimus 0.1% 3 SLE, 1 DLE
49 2 DLE tacrolimus 0.03% in 
clobetasol propionate 0.05%
2 DLE
50 1 DLE pimecrolimus 1% 1 DLE
51 1 LET tacrolimus 0.1% 1 LET
52 1 SLE, 2 SCLE tacrolimus 0.1% 1 SLE, 2 SCLE
53 3 SLE tacrolimus 0.1% 3 SLE
54 1 SCLE tacrolimus 0.1% 1 SCLE
55 1 DLE tacrolimus 0.1% 1 DLE
56 5 DLE, 4 SCLE, 2 SLE tacrolimus 0.1% 3 DLE, 2 SCLE, 2 SLE
57 4 DLE, 3 SLE, 2 SCLE, 2 LET pimecrolimus 1% 4 DLE, 3 SLE, 2 SCLE, 2 LET
58 10 DLE pimecrolimus 1% 10 DLE
60 5 DLE tacrolimus 0.1% 5 DLE
61 1 SCLE tacrolimus 0.1% 1 SCLE
62 1 SCLE tacrolimus 0.1% 1 SCLE
63 4 DLE tacrolimus 0.1% 4 DLE
64 2 SLE, 2 DLE tacrolimus 0,1% 1 SLE, 1 DLE
65 1 SLE/lichen planus tacrolimus 0.1% 1 SLE/lichen planus
66 13 SLE, 4 DLE, 1 SCLE tacrolimus 1% vs 
clobetasol propionate 0.05%
13 SLE, 4 DLE, 1 SCLE, 
fewer side effects
67  18 CLE  tacrolimus 0.3% plus 
clobetasol vs monotherapy
Better results with combination 
Abbreviations: CLE, cutaneous lupus erythematosus; DLE, discoid lupus erythematosus; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus; 
LET, lupus tumidus.Therapeutics and Clinical Risk Management 2010:6 98
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four DLE patients with facial rash, and four further patients 
with dermatomyositis. Improvement was noticed in all 
SLE patients but only in one with discoid lesions. Walker 
et al51 reported two patients with discoid lupus who showed 
significant improvement with tacrolimus ointment 0.03% 
in 0.05% clobetasol propionate cream while Zabawski52 
reported one patient with discoid lupus treated successfully 
with pimecrolimus cream 1%.
Tacrolimus was also effective in the treatment of one 
patient with lupus tumidus.53 Böhm et al54 successfully 
treated three patients (one with SLE and two with SCLE) 
with tacrolimus and Kanekura et al55 had the same results in 
three patients with SLE and facial skin lesions.
In 2004, Drüke et al56 and de la Rosa Carrillo et al57 treated 
one patient with SCLE and one patient with discoid lupus with 
tacrolimus. Lampropoulos et al58 published an open-label study 
of 11 patients comprising five with discoid lupus, four with 
SCLE and two with SLE. Tacrolimus ointment was applied 
twice daily for six weeks with a good response in both patients 
with SLE, two of four patients with SCLE (see Figure 1) and 
two patients with discoid lupus, while one patient with DLE 
had a partial response. A couple of months later an open uncon-
trolled clinical trial was published by Kreuter et al59 who used 
pimecrolimus 1% cream in 11 patients with different forms 
of lupus erythematosus comprising four with DLE, three with 
SLE, two with SCLE, and two with lupus tumidus. Pimecroli-
mus cream was applied twice daily for three weeks under semi-
occlusive conditions (overnight occlusion with hydrocolloid 
dressings) with significant improvement in all patients (57% 
improvement on a clinical severity score).
In 2005, Tlacuilo-Parra et al60 reported 10 patients with 
discoid lupus treated successfully with pimecrolimus for eight 
weeks. The overall improvement on a clinical severity score 
was 52%. Three patients showed a reduction of more than 
70%, four patients 50%–70%, and three patients 30%–50%. 
All patients had a skin biopsy before and after treatment which 
showed a significant reduction in the density of the dermal 
lymphocytic infiltrate. A quality of life index was also used 
(Skindex-29),61 with a mean improvement of 46%. In the same 
year Heffernan et al62 reported five patients with discoid lupus 
erythematosus who showed improvement of their rash after 
12 weeks of tacrolimus ointment. Meller et al63 described one 
patient with SCLE and Cassis et al64 a further patient with 
SCLE attributable to monocyclic antidepressant therapy who 
were treated successfully with tacrolimus.
Three publications concerning the use of calcineurin 
inhibitors and cutaneous lupus erythematosus were published 
in 2006. Sugano et al65 successfully treated four patients with 
discoid lupus using tacrolimus ointment for 4–8 weeks while 
von Pelchrzim et al66 had 50% success (one of two patients 
with SLE and one of two patients with DLE). Nagao et al67 
reported a patient with cutaneous lupus overlapping with 
lichen planus who was treated effectively with tacrolimus.
Tzung et al68 published the first randomized, double-blind, 
controlled study in 2007. Eighteen patients with facial rashes 
participated, of whom 13 had SLE, four had DLE and one had 
SCLE. Tacrolimus ointment was applied twice daily on one 
side of the face and clobetasol propionate 0.05% ointment on 
the other side. A partial response was noticed in all patients 
without significant differences between the two creams, but 
11 patients developed teleangiectasiae on the clobetasol side 
during the first three weeks, indicating better tolerability and 
safety of tacrolimus compared with topical steroids.
A retrospective study was published in 2009 by Madan 
et al.69 A specially formulated preparation of tacrolimus 
0.3% in clobetasol propionate 0.05% ointment was com-
pared with either 0.1% tacrolimus or clobetasol propionate 
0.05% as monotherapy in 18 patients with cutaneous lupus 
A B C D
Figure 1 Two patients with SCLE lesions on upper right limb and SCLE lesions on soles, respectively, before (A, C) and after (B, D) treatment with tacrolimus ointment. 
Copyright © 2004. Reprinted with permission from Lampropoulos CE, Sangle S, Harrison P, Hughes GR, D’Cruz DP. Topical tacrolimus therapy of resistant cutaneous lesions 
in lupus erythematosus: A possible alternative. Rheumatology (Oxford). 2004;43:1383–1385.
Abbreviation: SCLE, subacute cutaneous lupus erythematosus.Therapeutics and Clinical Risk Management 2010:6 99
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erythematosus, which seemed to be more effective. This is 
in accordance with experimental evidence that combination 
of corticosteroids with calcineurin inhibitors can achieve 
superior therapeutic efficacy and stronger inhibition of 
T-cell proliferation compared with monotherapy.70
Discussion
Cutaneous lesions in lupus erythematosus may prove very 
resistant to classical systemic and topical agents. These 
lesions usually appear in visible areas resulting in signifi-
cant psychological effects. Therapy is often unsatisfactory 
because of recalcitrant disease or serious side effects from 
corticosteroids.
Over the last two decades, tacrolimus and the newer 
calcineurin inhibitor pimecrolimus have emerged as effec-
tive immunosuppressive and anti-inflammatory agents. The 
experience in atopic dermatitis showed that they are very 
effective and safe, especially in children and for facial lesions 
where only weak topical steroids can be used. These oint-
ments are expensive, but a cost-effectiveness analysis showed 
that in the long term the cost is similar for tacrolimus and 
high-potency corticosteroids.71 They are not systemically 
absorbed, even when large areas of skin are affected, and 
their adverse reactions usually subside with continuation of 
treatment. Their use must be combined with sun protection 
because most of the cutaneous lesions in lupus are photo-
sensitive.
The usual effective treatment is application of the cream 
twice daily for at least four weeks, during which time 
improvement of symptoms is expected. Skin lesions in SLE 
can improve significantly in most patients, but this is less 
likely in patients with discoid lupus or SCLE. The response 
to treatment is partial in these particular types of cutane-
ous lupus and prolonged therapy may be needed, reflecting 
the chronicity and unresponsiveness of these lesions.72 
Nevertheless, 50%–60% of patients report a partial or good 
response, an encouraging result if we consider that these 
cutaneous lesions are usually resistant to systemic or other 
topical agents. Recent studies have shown that combination 
of calcineurin inhibitors with steroids is more effective than 
monotherapy, suggesting that this should be considered for 
very resistant lesions.
Most of the publications are case reports with small 
numbers of patients. The only randomized, double-blind 
study showed calcineurin inhibitors and steroids had simi-
lar efficacy but without serious side effects, reflecting the 
necessity for more prospective trials with larger numbers 
of patients. The warning issued by the FDA regarding the 
possible low risk of cancer should be considered by the 
prescribing physician, especially as these agents remain off-
label for use in lupus. A further consideration is the increased 
risk of lymphoma that is associated with having SLE,73 and 
so treatment should be limited to short periods of time. In 
conclusion, the data in the literature taken together suggest 
that topical calcineurin inhibitors can be considered to be a 
relatively safe and attractive alternative treatment for resistant 
cutaneous lesions in lupus erythematosus.
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